The life sciences technology company Graph AI, which focuses on patient safety and pharmacovigilance, has raised $3 million in a seed funding round headed by Bessemer Venture Partners.
The money raised will be utilized to increase the size of its engineering staff, speed up product development, and broaden its global enterprise clientele.
Graph AI, which was founded in 2024 by Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala, and Ashutosh Bordekar, is a regulatory process that involves pharmaceutical companies tracking and reporting adverse drug events (ADEs) over the course of a drug’s lifecycle. The market is worth $8 billion.
Currently, pharmaceutical companies use manual methods to extract and analyze data from unstructured sources like literature, medical reports, call logs, and court documents. These processes are automated by Graph AI’s flagship platform, Graph Safety, which uses intelligent automation and artificial intelligence.
It reduces human intervention to only necessary regulatory steps and supports ADE case processing, signal detection, aggregate reporting, and compliance.
Its system maintains audit readiness while centralizing safety data and increasing the accuracy of medical reviews. Faster compliance cycles and notable efficiency gains have been reported by enterprise clients utilizing the platform.
Professionals with past experience at Infosys, LTI Mindtree, ServiceNow, Google, and Cisco are part of Graph AI’s team. As it expands, it intends to build on its early customer traction across a pipeline of over 7,000 marketed medications.
